{"id":"depo-subq-provera","safety":{"commonSideEffects":[{"rate":"20–40","effect":"Irregular bleeding or amenorrhea"},{"rate":"5–10","effect":"Headache"},{"rate":"5–10","effect":"Breast tenderness"},{"rate":"2–5","effect":"Weight gain"},{"rate":"5–15","effect":"Injection site reactions"},{"rate":"2–5","effect":"Mood changes or depression"}]},"_chembl":{"chemblId":"CHEMBL717","moleculeType":"Small molecule","molecularWeight":"386.53"},"_dailymed":{"setId":"390087a6-f3c3-4f0b-a930-79acf412f153","title":"DEPO-SUBQ PROVERA (MEDROXYPROGESTERONE ACETATE) INJECTION, SUSPENSION [PHARMACIA & UPJOHN COMPANY LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Medroxyprogesterone acetate (MPA) is a synthetic progestin that acts on the hypothalamic-pituitary-ovarian axis to inhibit gonadotropin-releasing hormone (GnRH) secretion and suppress the LH surge necessary for ovulation. By preventing ovulation and thickening cervical mucus, it provides long-acting reversible contraception. The subcutaneous formulation delivers sustained hormone levels over 12–13 weeks per injection.","oneSentence":"Depo-subQ Provera is a progestin that suppresses the luteinizing hormone surge, preventing ovulation and providing contraceptive efficacy.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:01:44.087Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contraception (prevention of pregnancy)"}]},"trialDetails":[{"nctId":"NCT06665997","phase":"PHASE4","title":"Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-06-26","conditions":"Sickle Cell Disease (SCD), Vaso-Occlusive Pain Episode in Sickle Cell Disease","enrollment":65},{"nctId":"NCT05726903","phase":"PHASE4","title":"Counseling Among Gender Diverse Adolescents Who Use Depot Medroxyprogesterone","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2022-12-06","conditions":"Gender Dysphoria, Adolescent","enrollment":35},{"nctId":"NCT07148999","phase":"PHASE1, PHASE2","title":"An Advanced Decision Support Tool for Personalized Medicine for IVF Using Modeling and Optimization for Provera","status":"RECRUITING","sponsor":"Urmila DIwekar","startDate":"2025-09-23","conditions":"Infertility (IVF Patients)","enrollment":200},{"nctId":"NCT03689543","phase":"PHASE2","title":"Estrogen Receptor Beta and Mood","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2019-05-23","conditions":"Perimenopause-Related Depression","enrollment":74},{"nctId":"NCT05651282","phase":"PHASE4","title":"Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of British Columbia","startDate":"2023-03-15","conditions":"Endometrium Cancer","enrollment":250},{"nctId":"NCT05760144","phase":"EARLY_PHASE1","title":"Endometrial Biopsy in Progestin Contraceptive Users","status":"RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2023-07-01","conditions":"Contraception","enrollment":52},{"nctId":"NCT05056545","phase":"NA","title":"Postpartum Family Planning Program in Rwanda","status":"RECRUITING","sponsor":"Emory University","startDate":"2022-08-01","conditions":"Family Planning","enrollment":26215},{"nctId":"NCT02076217","phase":"","title":"Quick Start of Highly Effective Contraception","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Utah","startDate":"2014-02","conditions":"IUD, Contraceptive Implant, Contraception","enrollment":1030},{"nctId":"NCT06145438","phase":"PHASE3","title":"Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery","status":"COMPLETED","sponsor":"Universitas Diponegoro","startDate":"2023-09-04","conditions":"Endometriosis Ovary","enrollment":80},{"nctId":"NCT03660046","phase":"","title":"Contraceptive Hormones, Immunity, and Microbiome Evaluation","status":"COMPLETED","sponsor":"Emory University","startDate":"2018-12-07","conditions":"Hormonal Contraception","enrollment":155},{"nctId":"NCT00830414","phase":"PHASE1","title":"Medroxyprogesterone Acetate Injection 150 mg/1 mL in Postmenopausal Women","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2002-04","conditions":"Healthy","enrollment":124},{"nctId":"NCT03844633","phase":"PHASE4","title":"Postpartum Family Planning","status":"TERMINATED","sponsor":"Ohio State University","startDate":"2019-03-21","conditions":"Delay in Time to Lactogenesis Stage II","enrollment":49},{"nctId":"NCT04682353","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of Reproductive Age","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2020-12-14","conditions":"Contraception","enrollment":60},{"nctId":"NCT00577122","phase":"PHASE2","title":"Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Indiana University","startDate":"2007-07","conditions":"Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer","enrollment":30},{"nctId":"NCT05973253","phase":"PHASE2, PHASE3","title":"Evaluation of Efficacy and Safety of Topical 1% Medroxyprogesterone in the Corneal Epithelium Healing After PRK","status":"COMPLETED","sponsor":"Isfahan University of Medical Sciences","startDate":"2023-04-21","conditions":"Photorefractive Keratectomy","enrollment":74},{"nctId":"NCT03916328","phase":"PHASE4","title":"BONE: STAR (Switching to TAF Based Anti-Retroviral Therapy) Study","status":"UNKNOWN","sponsor":"MU-JHU CARE","startDate":"2019-12-03","conditions":"Bone Loss","enrollment":330},{"nctId":"NCT05742503","phase":"","title":"Progesterone Containing Contraceptive Methods on Endogenous Progesterone Level","status":"COMPLETED","sponsor":"Tanta University","startDate":"2021-03-30","conditions":"Progesterone, Contraceptive Methods","enrollment":80},{"nctId":"NCT03675139","phase":"PHASE3","title":"MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia","status":"COMPLETED","sponsor":"Xiaojun Chen","startDate":"2019-02-26","conditions":"Endometrial Hyperplasia Without Atypia","enrollment":471},{"nctId":"NCT04021017","phase":"PHASE1","title":"PRE-GAiN Bone Health Pilot Study","status":"WITHDRAWN","sponsor":"University of Saskatchewan","startDate":"2020-01-21","conditions":"Anorexia Nervosa","enrollment":""},{"nctId":"NCT05491343","phase":"PHASE4","title":"Observation vs Progesterone Treatment for Management of Uterine Arteriovenous Malformation","status":"UNKNOWN","sponsor":"HaEmek Medical Center, Israel","startDate":"2022-08","conditions":"Arteriovenous Malformations","enrollment":28},{"nctId":"NCT02449161","phase":"PHASE3","title":"The Effect of Post Ablation Medroxyprogesterone Acetate on Endometrial Amenorrhea Rates","status":"TERMINATED","sponsor":"Guy Waddell","startDate":"2015-08","conditions":"Menorrhagia","enrollment":60},{"nctId":"NCT01174225","phase":"PHASE4","title":"IUD Insertion Post First Trimester Abortion","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2010-09","conditions":"Contraception","enrollment":534},{"nctId":"NCT02353247","phase":"NA","title":"Use of Norethindrone Acetate for Management of Bleeding Associated With the Etonogestrel Contraceptive Implant","status":"COMPLETED","sponsor":"Norton Healthcare","startDate":"2015-08","conditions":"Etonogestrel Contraceptive Implant, Bothersome Bleeding","enrollment":88},{"nctId":"NCT04887402","phase":"","title":"Parameters Declaring PCO Infertile Patients Either Sensitive or Resistant to Different Doses of Clomiphene Citrate.","status":"UNKNOWN","sponsor":"Ain Shams Maternity Hospital","startDate":"2021-01-01","conditions":"PCO, Induction of Ovulation, Clomiphene Citrate","enrollment":100},{"nctId":"NCT00745108","phase":"PHASE3","title":"Tibolone Endometrium Study (Study 32972)(P06470)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-10-01","conditions":"Postmenopausal Women","enrollment":32},{"nctId":"NCT03700658","phase":"PHASE1","title":"A Study to Evaluate Injection Pain and Local Tolerability Following Subcutaneous (SC) Administration of TV-46046","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2019-01-15","conditions":"Contraception","enrollment":27},{"nctId":"NCT02122198","phase":"NA","title":"Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2014-09-08","conditions":"Cognitive Impairment, Executive Dysfunction, Endothelial Dysfunction","enrollment":17},{"nctId":"NCT01873170","phase":"","title":"Quantification of Immune Cells in Women Using Contraception (CHIC II)","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2013-08","conditions":"HIV, Immune Cells (Mucosal and Systemic), Contraception","enrollment":326},{"nctId":"NCT00563576","phase":"NA","title":"Pilot Study of Femring Estrogen Supplementation During Depo-Provera Initiation","status":"COMPLETED","sponsor":"Columbia University","startDate":"2007-09","conditions":"Metrorrhagia","enrollment":71},{"nctId":"NCT05138367","phase":"PHASE1","title":"Effects of UCA-PSCs in Women With POF","status":"COMPLETED","sponsor":"Li-jun Ding","startDate":"2018-12-01","conditions":"Premature Ovarian Failure","enrollment":20},{"nctId":"NCT03018249","phase":"EARLY_PHASE1","title":"Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-10-11","conditions":"FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma","enrollment":50},{"nctId":"NCT00088153","phase":"PHASE2, PHASE3","title":"Effects of Anorexia Nervosa on Bone Mass in Adolescents","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2003-07","conditions":"Anorexia Nervosa","enrollment":110},{"nctId":"NCT03300960","phase":"PHASE3","title":"Usefulness of Medroxyprogesterone Acetate in Follicular Phase in Oocyte Donors. Undergoing Ovarian Stimulation","status":"COMPLETED","sponsor":"Instituto Valenciano de Infertilidad, IVI VALENCIA","startDate":"2017-10-20","conditions":"Infertility","enrollment":318},{"nctId":"NCT00743574","phase":"NA","title":"Health Benefits of Vitamin D and Calcium in Women With PCOS (Polycystic Ovarian Syndrome)","status":"COMPLETED","sponsor":"Yale University","startDate":"2008-08","conditions":"Polycystic Ovarian Syndrome, Vitamin D Deficiency","enrollment":36},{"nctId":"NCT03196492","phase":"","title":"Vaginal Microbiota, and STI/HIV Risk Among Adolescent Girls and Young Women","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2017-06-14","conditions":"Microbial Colonization","enrollment":234},{"nctId":"NCT03255941","phase":"EARLY_PHASE1","title":"Clinical Study of Depo Provera Comparing Lay Health Workers and Clinically-trained Health Workers","status":"COMPLETED","sponsor":"FHI 360","startDate":"2018-03-19","conditions":"Contraception","enrollment":460},{"nctId":"NCT02357368","phase":"PHASE4","title":"Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk","status":"COMPLETED","sponsor":"Lisa Haddad","startDate":"2015-02","conditions":"HIV, Contraception","enrollment":59},{"nctId":"NCT02419690","phase":"NA","title":"Sexual Health Texting Intervention to Support Adolescent Females","status":"COMPLETED","sponsor":"Denver Health and Hospital Authority","startDate":"2015-04","conditions":"Teen Sexual Health","enrollment":244},{"nctId":"NCT01718444","phase":"NA","title":"Progestin-induced Endometrial Shedding in PCOS (The PIES in PCOS Study)","status":"TERMINATED","sponsor":"University of Illinois at Chicago","startDate":"2015-03","conditions":"Polycystic Ovary Syndrome, Infertility","enrollment":27},{"nctId":"NCT02509767","phase":"PHASE4","title":"Depo Provera Self-Administration Study: Putting a Patient-Centered Practice to the Test at Planned Parenthood","status":"COMPLETED","sponsor":"Planned Parenthood Federation of America","startDate":"2015-08","conditions":"Contraception","enrollment":401},{"nctId":"NCT02922348","phase":"PHASE3","title":"Hormone Replacement for Premature Ovarian Insufficiency","status":"WITHDRAWN","sponsor":"University of Pennsylvania","startDate":"2016-03-01","conditions":"Primary Ovarian Insufficiency","enrollment":""},{"nctId":"NCT01019369","phase":"NA","title":"Study of Self or Clinic Administration of DepoProvera","status":"COMPLETED","sponsor":"Carolyn L. Westhoff","startDate":"2010-03","conditions":"Contraception","enrollment":132},{"nctId":"NCT01074892","phase":"PHASE4","title":"A Study Comparing Mirena and Systemic Progestin for Endometrial Hyperplasia","status":"COMPLETED","sponsor":"University Hospital of North Norway","startDate":"2005-05","conditions":"Endometrial Hyperplasia","enrollment":170},{"nctId":"NCT02456584","phase":"PHASE1","title":"Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods","status":"COMPLETED","sponsor":"FHI 360","startDate":"2015-09","conditions":"Contraception","enrollment":42},{"nctId":"NCT00437658","phase":"PHASE2","title":"Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2006-12-11","conditions":"Endometriosis","enrollment":252},{"nctId":"NCT01607320","phase":"NA","title":"Efficacy Study of Raloxifene to Induce Ovulation in Polycystic Ovarian Syndrome","status":"TERMINATED","sponsor":"Bruce Lessey","startDate":"2012-06","conditions":"Polycystic Ovarian Syndrome","enrollment":3},{"nctId":"NCT02657148","phase":"","title":"Immediate Postpartum Nexplanon Placement in Opioid Dependent Women","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2016-05","conditions":"Opiate Addiction, Pregnancy, Contraceptive Behavior","enrollment":200},{"nctId":"NCT01463202","phase":"PHASE4","title":"Timing of Postpartum Depot Medroxyprogesterone Acetate Administration on Breastfeeding, Contraceptive Continuation, and Depression","status":"COMPLETED","sponsor":"Beatrice Chen","startDate":"2011-11","conditions":"Contraception, Postpartum Depression, Lactation","enrollment":184},{"nctId":"NCT02103764","phase":"PHASE3","title":"Efficacy of Cyclic DSG Compared With Cyclic MPA for the Treatment of Anovulatory DUB","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2013-08","conditions":"Dysfunctional Uterine Bleeding","enrollment":160},{"nctId":"NCT02740998","phase":"","title":"Long-Acting Progestin Contraception and the Vaginal Microbiome","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2016-03","conditions":"Sexually Transmitted Infection","enrollment":28},{"nctId":"NCT00302731","phase":"PHASE2","title":"Bioidentical 'Natural' Hormone Evaluation in Early Menopause","status":"TERMINATED","sponsor":"Jeanne Drisko, MD, CNS, FACN","startDate":"2006-02","conditions":"Menopause","enrollment":21},{"nctId":"NCT02732418","phase":"PHASE1","title":"Lower Dose Depo Provera® Contraceptive Injection","status":"COMPLETED","sponsor":"FHI 360","startDate":"2016-12-02","conditions":"Contraception","enrollment":60},{"nctId":"NCT03309176","phase":"PHASE4","title":"\"Stair Step Study\"","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2016-06-21","conditions":"Ovulation Disorder","enrollment":42},{"nctId":"NCT03377608","phase":"","title":"Modifiers of Tenofovir in the Female Genital Tract","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2017-11-17","conditions":"HIV/AIDS, Contraception","enrollment":50},{"nctId":"NCT01461824","phase":"PHASE3","title":"Drug Exposure and Depot Medroxyprogesterone Acetate (DMPA) in Adolescent Subjects","status":"COMPLETED","sponsor":"Nationwide Children's Hospital","startDate":"2011-09","conditions":"Weight Gain, Disorder of Bone Density and Structure, Unspecified, Uterine Bleeding","enrollment":34},{"nctId":"NCT02103660","phase":"PHASE4","title":"Clinical Trial on the Effects of Progestin-based Contraception in the Genital Tract of HIV-infected and Uninfected Women","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2014-04-08","conditions":"HIV, Contraception","enrollment":131},{"nctId":"NCT01299116","phase":"PHASE4","title":"Long-Acting Reversible Contraception","status":"COMPLETED","sponsor":"FHI 360","startDate":"2011-12","conditions":"Contraception","enrollment":916},{"nctId":"NCT01008319","phase":"PHASE3","title":"Traditional Clomiphene Citrate Administration vs. Stair-step Approach","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2009-10","conditions":"Ovulatory Dysfunction, Anovulation, Ovulation Induction","enrollment":120},{"nctId":"NCT01356927","phase":"","title":"Same-day Long-acting Reversible Contraception for Medication Abortion","status":"COMPLETED","sponsor":"Boston University","startDate":"2011-05","conditions":"Abortion; Induced","enrollment":40},{"nctId":"NCT01385709","phase":"","title":"The Influence of the Menstrual Cycle on Lithium and Sertraline Blood Levels","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2008-08","conditions":"Bipolar Affective Disorders, Cyclothymic Disorder, Schizoaffective Disorder","enrollment":29},{"nctId":"NCT02335203","phase":"PHASE2","title":"The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy","status":"UNKNOWN","sponsor":"Women and Infants Hospital of Rhode Island","startDate":"2015-02","conditions":"Grade 1 Endometrial Endometrioid Adenocarcinoma, Grade 2 Endometrial Endometrioid Adenocarcinoma, Complex Atypical Endometrial Hyperplasia","enrollment":76},{"nctId":"NCT00083824","phase":"PHASE2, PHASE3","title":"Estrogen, HDL, and Coronary Heart Disease in Women","status":"COMPLETED","sponsor":"Tufts University","startDate":"2004-03","conditions":"Cardiovascular Diseases, Coronary Disease, Heart Diseases","enrollment":309},{"nctId":"NCT00064025","phase":"PHASE2","title":"Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","startDate":"2004-04","conditions":"Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation","enrollment":75},{"nctId":"NCT00797199","phase":"","title":"Monitoring of Breast Tissue Change Due to Hormone Replacement Therapy in Post-menopausal Women Using OBS","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2011-09","conditions":"Breast Cancer","enrollment":14},{"nctId":"NCT01296152","phase":"PHASE2","title":"Pharmacokinetic Interactions Between DMPA and LPV/r Among HIV-Infected Women","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-05","conditions":"HIV-1 Infection","enrollment":25},{"nctId":"NCT02340013","phase":"PHASE4","title":"Endometrial Shedding Prior to Ovulation Induction Pilot Study","status":"COMPLETED","sponsor":"Samuel Lunenfeld Research Institute, Mount Sinai Hospital","startDate":"2013-07","conditions":"Infertility","enrollment":50},{"nctId":"NCT01421368","phase":"PHASE1","title":"Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use","status":"COMPLETED","sponsor":"CONRAD","startDate":"2012-03","conditions":"HIV Prevention","enrollment":72},{"nctId":"NCT01776203","phase":"PHASE4","title":"Study of a Progestin to Prevent Bleeding Associated With Initiation of Medical Menopause With GnRH Agonist","status":"TERMINATED","sponsor":"Kaiser Permanente","startDate":"2012-01","conditions":"Dysfunctional Uterine Bleeding","enrollment":8},{"nctId":"NCT00350480","phase":"NA","title":"Treatment of Non-Gestational Acute Uterine Bleeding: A Randomized Trial","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2003-04","conditions":"Uterine Hemorrhage, Menorrhagia","enrollment":240},{"nctId":"NCT01966575","phase":"PHASE4","title":"Effect of Progestin-Induced Withdrawal Bleed on Ovulation Induction Cycles With Clomiphene Citrate","status":"WITHDRAWN","sponsor":"University of British Columbia","startDate":"2013-10","conditions":"Polycystic Ovary Syndrome, Infertility","enrollment":""},{"nctId":"NCT01056042","phase":"PHASE4","title":"Efficacy of Injectable Contraceptive and Oral Contraceptive Administered After Surgical Treatment of Endometriosis With Pain","status":"COMPLETED","sponsor":"Prince of Songkla University","startDate":"2007-06","conditions":"Endometriosis","enrollment":112},{"nctId":"NCT01578447","phase":"NA","title":"Acceptability of Depo-subQ Provera 104 in Uniject vs. Intramuscular Depo-Provera Among HIV+ Women & Providers, Uganda","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2012-04","conditions":"Acceptability of Different Contraceptive Injection Types","enrollment":356},{"nctId":"NCT01148420","phase":"PHASE4","title":"DMPA & High Dose Oral Progestin (MPA) Tablets in Outpatient Treatment of Acute Excessive Vaginal Bleeding","status":"COMPLETED","sponsor":"Women's Health Care Clinic, Torrance, California","startDate":"2009-01","conditions":"Dysfunctional Uterine Bleeding","enrollment":48},{"nctId":"NCT01750476","phase":"","title":"Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives","status":"TERMINATED","sponsor":"Thomas Cherpes, DVM, MD","startDate":"2012-12","conditions":"Initiation of Oral Contraception (OC), Initiation of Depo-Provera (DMPA), Initiation of Mirena (LNG-IUD)","enrollment":7},{"nctId":"NCT00360490","phase":"PHASE3","title":"Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-07","conditions":"Menorrhagia","enrollment":165},{"nctId":"NCT00490555","phase":"PHASE2, PHASE3","title":"PROS-1-Male Hormonal Contraceptive Regimens on Prostate Tissue","status":"COMPLETED","sponsor":"University of Washington","startDate":"2009-01","conditions":"Healthy","enrollment":32},{"nctId":"NCT01191203","phase":"NA","title":"Randomized Control Trial Copper Intrauterine Device and Depo-medroxyprogesterone Acetate (DMPA) of HIV+ Women in Malawi","status":"COMPLETED","sponsor":"Emory University","startDate":"2010-07","conditions":"HIV","enrollment":200},{"nctId":"NCT00253019","phase":"","title":"A Comparison of Continuation Rates for Three Hormonal Contraceptive Methods","status":"COMPLETED","sponsor":"Emory University","startDate":"2004-10","conditions":"Contraception","enrollment":321},{"nctId":"NCT01143207","phase":"NA","title":"PK of Depo SubQ Injected in the Upper Arm","status":"COMPLETED","sponsor":"FHI 360","startDate":"2010-05","conditions":"Contraception","enrollment":26},{"nctId":"NCT00000419","phase":"PHASE3","title":"Safety of Estrogens in Lupus: Hormone Replacement Therapy","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"1996-04","conditions":"Systemic Lupus Erythematosus","enrollment":350},{"nctId":"NCT00033358","phase":"PHASE2","title":"Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-02","conditions":"Endometrial Cancer","enrollment":52},{"nctId":"NCT00123175","phase":"PHASE1, PHASE2","title":"Treatment of Endometrial Hyperplasia With an Intrauterine Device (IUD)","status":"WITHDRAWN","sponsor":"Milton S. Hershey Medical Center","startDate":"2009-09","conditions":"Endometrial Hyperplasia","enrollment":""},{"nctId":"NCT00016601","phase":"NA","title":"Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-06","conditions":"HIV Infections","enrollment":76},{"nctId":"NCT01592058","phase":"","title":"Weight Change Among Users of Three Progestin-Only Methods of Contraception Over a 12-Month Time Period","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2010-06","conditions":"Weight Change","enrollment":427},{"nctId":"NCT00807625","phase":"PHASE2","title":"Impact of Different Contraceptives on the Immune System of HIV Infected Women in Zambia","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2008-11","conditions":"HIV, Contraception, HIV Infections","enrollment":66},{"nctId":"NCT00770887","phase":"","title":"Self Administration of Subcutaneous Depot Medroxyprogesterone Acetate","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2010-05","conditions":"Fertility","enrollment":50},{"nctId":"NCT00543634","phase":"PHASE1","title":"Study Comparing Premarin®/MPA, PREMPRO® and Provera® in Healthy Postmenopausal Women","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-10","conditions":"Postmenopause","enrollment":30},{"nctId":"NCT01087593","phase":"NA","title":"Estrogens Effect on Pain in Postmenopausal Women Suffering of Fibromyalgia","status":"TERMINATED","sponsor":"Ostergotland County Council, Sweden","startDate":"2001-08","conditions":"Fibromyalgia","enrollment":29},{"nctId":"NCT00775047","phase":"NA","title":"Pharmacist-Administered Injections for Contraception","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2006-08","conditions":"Contraception","enrollment":50},{"nctId":"NCT00139685","phase":"PHASE4","title":"Depo-Provera: Bone Mineral Density and Total Body Calcium in Adolescent DP150CI Users and Non-Hormonal Contraception","status":"COMPLETED","sponsor":"Pfizer","startDate":"1998-04","conditions":"Contraception, Bone Density","enrollment":350}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[{"date":"20160229","type":"SUPPL","sponsor":"PFIZER","applicationNumber":"NDA021583"},{"date":"20090715","type":"SUPPL","sponsor":"PFIZER","applicationNumber":"NDA021583"},{"date":"20071005","type":"SUPPL","sponsor":"PFIZER","applicationNumber":"NDA021583"},{"date":"20041217","type":"ORIG","sponsor":"PFIZER","applicationNumber":"NDA021583"},{"date":"20201204","type":"SUPPL","sponsor":"PFIZER","applicationNumber":"NDA021583"},{"date":"20150123","type":"SUPPL","sponsor":"PFIZER","applicationNumber":"NDA021583"},{"date":"20240711","type":"SUPPL","sponsor":"PFIZER","applicationNumber":"NDA021583"},{"date":"20161014","type":"SUPPL","sponsor":"PFIZER","applicationNumber":"NDA021583"},{"date":"20191223","type":"SUPPL","sponsor":"PFIZER","applicationNumber":"NDA021583"},{"date":"20191223","type":"SUPPL","sponsor":"PFIZER","applicationNumber":"NDA021583"},{"date":"20051108","type":"SUPPL","sponsor":"PFIZER","applicationNumber":"NDA021583"},{"date":"20050502","type":"SUPPL","sponsor":"PFIZER","applicationNumber":"NDA021583"},{"date":"20251212","type":"SUPPL","sponsor":"PFIZER","applicationNumber":"NDA021583"},{"date":"20191223","type":"SUPPL","sponsor":"PFIZER","applicationNumber":"NDA021583"},{"date":"20241216","type":"SUPPL","sponsor":"PFIZER","applicationNumber":"NDA021583"},{"date":"20160804","type":"SUPPL","sponsor":"PFIZER","applicationNumber":"NDA021583"},{"date":"20201204","type":"SUPPL","sponsor":"PFIZER","applicationNumber":"NDA021583"},{"date":"20150130","type":"SUPPL","sponsor":"PFIZER","applicationNumber":"NDA021583"},{"date":"20180301","type":"SUPPL","sponsor":"PFIZER","applicationNumber":"NDA021583"},{"date":"20161216","type":"SUPPL","sponsor":"PFIZER","applicationNumber":"NDA021583"},{"date":"20170131","type":"SUPPL","sponsor":"PFIZER","applicationNumber":"NDA021583"}],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Depo-subQ Provera","genericName":"Depo-subQ Provera","companyName":"Teva Branded Pharmaceutical Products R&D, Inc.","companyId":"teva-branded-pharmaceutical-products-r-d-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Depo-subQ Provera is a small molecule that acts as a progesterone receptor agonist. It is used to treat conditions such as Polycystic Ovarian Syndrome and to induce ovulation, among other indications.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"supplemented","approval_date":"2004-12-17T00:00:00.000Z","mah":"PFIZER","brand_name_local":null,"application_number":"NDA021583"}],"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}